BioMarin obtains notice of allowance for phenylketonuria drug
The company expects that the patent will be officially issued later in 2009, and if issued, the patent’s initial 20-year term would expire in 2024. The company said
Australia-based Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn, combining Telix’s operations with ITM’s radioisotope production business and late-stage treatment candidate ITM-11.
Emtricitabine and tenofovir disoproxil fumarate tablets are the generic version of Gilead Sciences’s Truvada tablets. Truvada is a second-line anti-HIV drug in the nucleoside reverse transcriptase inhibitor family
Switzerland-based biotechnology company ESBATech has announced encouraging preclinical results, which demonstrate efficacy of topical ESBA105, an antitumor necrosis factor single-chain antibody fragment, in a model for choroidal neovascularization.